| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider activity in EVGN over the last quarter tilts toward buying: insiders added a net 1,260,000 shares worth roughly $692K.
EVGN sits in the Biotechnology industry within the Healthcare sector, so this activity is best read against the sector's broader insider trend.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 10.0K | - | - | |
| Dir | 2.5K | - | - | |
| Dir | 2.5K | - | - | |
| Dir | 2.5K | - | - | |
| Other | 1.1K | $677.40 | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 11, 2026 | Recanati Leon | Director | Buy | 460,000 | $0.64 | $292,100.00 | +52.0% | |
| Aug 4, 2026 | Recanati Leon | Director | Buy | 800,000 | $0.50 | $400,000.00 | +953.7% | |
| Jun 4, 2026 | Tarcic Gabi | Chief Development Officer | Buy | 1,129 | $0.60 | $677.40 | New |